Archives of Virology

, Volume 155, Issue 4, pp 601–605 | Cite as

Hydroxyurea as an inhibitor of hepatitis C virus RNA replication

  • Akito NozakiEmail author
  • Manabu Morimoto
  • Masaaki Kondo
  • Takashi Oshima
  • Kazushi Numata
  • Shin Fujisawa
  • Takeshi Kaneko
  • Eiji Miyajima
  • Satoshi Morita
  • Kyoko Mori
  • Masanori Ikeda
  • Nobuyuki Kato
  • Katsuaki Tanaka
Brief Report


Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.


Internal Ribosome Entry Site Human Immunodeficiency Virus Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Kazue Yoshihara and Yoshiko Kubushiro for their technical assistance. This work was supported by a grant for the 2008 Strategic Research Project (No. W20012) provided by Yokohama City University, Japan.


  1. 1.
    Adams RL, Lindsay JG (1967) Hydroxyurea reversal of inhibition and use as a cell-synchronizing agent. J Biol Chem 242:1314–1317PubMedGoogle Scholar
  2. 2.
    Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M (2008) Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103:1383–1389CrossRefPubMedGoogle Scholar
  3. 3.
    Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 46:455–462CrossRefPubMedGoogle Scholar
  4. 4.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362CrossRefPubMedGoogle Scholar
  5. 5.
    Foli A, Maiocchi MA, Lisziewicz J, Lori F (2007) A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis 196:1409–1415CrossRefPubMedGoogle Scholar
  6. 6.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FLJ, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982CrossRefPubMedGoogle Scholar
  7. 7.
    Garcia M, Yu XF, Griffin DE, Moss WJ (2008) Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol 89:984–993CrossRefPubMedGoogle Scholar
  8. 8.
    Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E (1996) Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 87:5384–5391PubMedGoogle Scholar
  9. 9.
    Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329:1350–1359CrossRefPubMedGoogle Scholar
  10. 10.
    Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117–125CrossRefPubMedGoogle Scholar
  11. 11.
    Ikeda M, Kato N (2007) Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 59:1277–1289CrossRefPubMedGoogle Scholar
  12. 12.
    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo WS, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364CrossRefPubMedGoogle Scholar
  13. 13.
    Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801–805CrossRefPubMedGoogle Scholar
  14. 14.
    Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J (1999) Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 180:1827–1832CrossRefPubMedGoogle Scholar
  15. 15.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965CrossRefPubMedGoogle Scholar
  16. 16.
    Mori K, Abe K, Dansako H, Ariumi Y, Ikeda M, Kato N (2008) New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochem Biophys Res Commun 371:104–109CrossRefPubMedGoogle Scholar
  17. 17.
    Naka K, Ikeda M, Abe K, Dansako H, Kato N (2005) Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-α. Biochem Biophys Res Commun 330:871–879CrossRefPubMedGoogle Scholar
  18. 18.
    Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 75:1252–1264CrossRefPubMedGoogle Scholar
  19. 19.
    Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo QL, Houghton M, Kuo G (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87:6547–6549CrossRefPubMedGoogle Scholar
  20. 20.
    Sergerie Y, Boivin G (2008) Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes. Antiviral Res 77:77–80CrossRefPubMedGoogle Scholar
  21. 21.
    Tamura T, Matsuzaki M, Harada H, Ogawa K, Mohri H, Okubo T (1997) Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. J Investig Med 45:160–167PubMedGoogle Scholar
  22. 22.
    Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, Kakinuma S, Watanabe M (2004) Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 189:1129–1139CrossRefPubMedGoogle Scholar
  23. 23.
    The Benelux CML, Group Study (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 91:2713–2721Google Scholar
  24. 24.
    Thomas DL (2000) Hepatitis C epidemiology. Curr Top Microbiol Immunol 242:25–41PubMedGoogle Scholar
  25. 25.
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288CrossRefPubMedGoogle Scholar
  26. 26.
    Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19:111–122CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Akito Nozaki
    • 1
    • 2
    Email author
  • Manabu Morimoto
    • 1
  • Masaaki Kondo
    • 1
  • Takashi Oshima
    • 1
  • Kazushi Numata
    • 1
  • Shin Fujisawa
    • 3
  • Takeshi Kaneko
    • 4
  • Eiji Miyajima
    • 5
  • Satoshi Morita
    • 6
  • Kyoko Mori
    • 7
  • Masanori Ikeda
    • 7
  • Nobuyuki Kato
    • 7
  • Katsuaki Tanaka
    • 1
  1. 1.Gastroenterological CenterYokohama City University Medical CenterYokohamaJapan
  2. 2.Department of Transfusion MedicineYokohama City University Medical CenterYokohamaJapan
  3. 3.Department of HematologyYokohama City University Medical CenterYokohamaJapan
  4. 4.Respiratory Disease CenterYokohama City University Medical CenterYokohamaJapan
  5. 5.Department of Laboratory Medicine and Clinical InvestigationYokohama City University Medical CenterYokohamaJapan
  6. 6.Department of Biostatistics and EpidemiologyYokohama City University Medical CenterYokohamaJapan
  7. 7.Department of Tumor VirologyOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan

Personalised recommendations